Oxidative stress change by systemic corticosteroid treatment among patients having active graves ophthalmopathy

Chieh Chih Tsai, Shu Ching Kao, Ching Yu Cheng, Hui Chuan Kau, Wen-Ming Hsu, Cheng Feng Lee, Yau Huei Wei

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Objectives: To measure the 8-hydroxy-2′-deoxyguanosine (8-OHdG) level in patients having active Graves ophthalmopathy (GO) and to compare this oxidative stress biomarker and the clinical evolution of patients after systemic corticosteroid treatment. Methods: In 8 euthyroid patients having active GO, we determined the 8-OHdG levels in urine before, during, and after intensive corticosteroid therapy. Clinical activity and ophthalmopathy index scores were assessed. Nine age- and sex-matched healthy volunteers served as control subjects. Results: The mean 8-OHdG level was statistically significantly increased in patients having active GO compared with that of controls (17.47 vs 5.97 ng/mg of creatinine, P < .001). During and after maximal systemic corticosteroid treatment, patients had statistically significantly lower mean 8-OHdG levels (7.19 and 10.18 ng/mg of creatinine, respectively) compared with the mean level before treatment. These changes were accompanied by decreases in clinical activity and ophthalmopathy index scores. The urinary 8-OHdG levels were subsequently elevated in 2 patients having recurrent active GO when corticosteroid therapy was tapered or withdrawn. Conclusions: Oxidative stress may have a role in the pathogenesis of GO. Urinary 8-OHdG level can be used not only as a noninvasive biomarker of oxidative stress in patients having GO but also as an objective and quantitative parameter in the follow-up of patients during immunosuppressive treatment.

Original languageEnglish
Pages (from-to)1652-1656
Number of pages5
JournalArchives of Ophthalmology
Volume125
Issue number12
DOIs
Publication statusPublished - Dec 1 2007
Externally publishedYes

Fingerprint

Graves Ophthalmopathy
Adrenal Cortex Hormones
Oxidative Stress
Therapeutics
Creatinine
Biomarkers
Immunosuppressive Agents
Healthy Volunteers
Urine

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Oxidative stress change by systemic corticosteroid treatment among patients having active graves ophthalmopathy. / Tsai, Chieh Chih; Kao, Shu Ching; Cheng, Ching Yu; Kau, Hui Chuan; Hsu, Wen-Ming; Lee, Cheng Feng; Wei, Yau Huei.

In: Archives of Ophthalmology, Vol. 125, No. 12, 01.12.2007, p. 1652-1656.

Research output: Contribution to journalArticle

Tsai, Chieh Chih ; Kao, Shu Ching ; Cheng, Ching Yu ; Kau, Hui Chuan ; Hsu, Wen-Ming ; Lee, Cheng Feng ; Wei, Yau Huei. / Oxidative stress change by systemic corticosteroid treatment among patients having active graves ophthalmopathy. In: Archives of Ophthalmology. 2007 ; Vol. 125, No. 12. pp. 1652-1656.
@article{2df4a51958fc47f9a5b8ee158946d5b5,
title = "Oxidative stress change by systemic corticosteroid treatment among patients having active graves ophthalmopathy",
abstract = "Objectives: To measure the 8-hydroxy-2′-deoxyguanosine (8-OHdG) level in patients having active Graves ophthalmopathy (GO) and to compare this oxidative stress biomarker and the clinical evolution of patients after systemic corticosteroid treatment. Methods: In 8 euthyroid patients having active GO, we determined the 8-OHdG levels in urine before, during, and after intensive corticosteroid therapy. Clinical activity and ophthalmopathy index scores were assessed. Nine age- and sex-matched healthy volunteers served as control subjects. Results: The mean 8-OHdG level was statistically significantly increased in patients having active GO compared with that of controls (17.47 vs 5.97 ng/mg of creatinine, P < .001). During and after maximal systemic corticosteroid treatment, patients had statistically significantly lower mean 8-OHdG levels (7.19 and 10.18 ng/mg of creatinine, respectively) compared with the mean level before treatment. These changes were accompanied by decreases in clinical activity and ophthalmopathy index scores. The urinary 8-OHdG levels were subsequently elevated in 2 patients having recurrent active GO when corticosteroid therapy was tapered or withdrawn. Conclusions: Oxidative stress may have a role in the pathogenesis of GO. Urinary 8-OHdG level can be used not only as a noninvasive biomarker of oxidative stress in patients having GO but also as an objective and quantitative parameter in the follow-up of patients during immunosuppressive treatment.",
author = "Tsai, {Chieh Chih} and Kao, {Shu Ching} and Cheng, {Ching Yu} and Kau, {Hui Chuan} and Wen-Ming Hsu and Lee, {Cheng Feng} and Wei, {Yau Huei}",
year = "2007",
month = "12",
day = "1",
doi = "10.1001/archopht.125.12.1652",
language = "English",
volume = "125",
pages = "1652--1656",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "12",

}

TY - JOUR

T1 - Oxidative stress change by systemic corticosteroid treatment among patients having active graves ophthalmopathy

AU - Tsai, Chieh Chih

AU - Kao, Shu Ching

AU - Cheng, Ching Yu

AU - Kau, Hui Chuan

AU - Hsu, Wen-Ming

AU - Lee, Cheng Feng

AU - Wei, Yau Huei

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Objectives: To measure the 8-hydroxy-2′-deoxyguanosine (8-OHdG) level in patients having active Graves ophthalmopathy (GO) and to compare this oxidative stress biomarker and the clinical evolution of patients after systemic corticosteroid treatment. Methods: In 8 euthyroid patients having active GO, we determined the 8-OHdG levels in urine before, during, and after intensive corticosteroid therapy. Clinical activity and ophthalmopathy index scores were assessed. Nine age- and sex-matched healthy volunteers served as control subjects. Results: The mean 8-OHdG level was statistically significantly increased in patients having active GO compared with that of controls (17.47 vs 5.97 ng/mg of creatinine, P < .001). During and after maximal systemic corticosteroid treatment, patients had statistically significantly lower mean 8-OHdG levels (7.19 and 10.18 ng/mg of creatinine, respectively) compared with the mean level before treatment. These changes were accompanied by decreases in clinical activity and ophthalmopathy index scores. The urinary 8-OHdG levels were subsequently elevated in 2 patients having recurrent active GO when corticosteroid therapy was tapered or withdrawn. Conclusions: Oxidative stress may have a role in the pathogenesis of GO. Urinary 8-OHdG level can be used not only as a noninvasive biomarker of oxidative stress in patients having GO but also as an objective and quantitative parameter in the follow-up of patients during immunosuppressive treatment.

AB - Objectives: To measure the 8-hydroxy-2′-deoxyguanosine (8-OHdG) level in patients having active Graves ophthalmopathy (GO) and to compare this oxidative stress biomarker and the clinical evolution of patients after systemic corticosteroid treatment. Methods: In 8 euthyroid patients having active GO, we determined the 8-OHdG levels in urine before, during, and after intensive corticosteroid therapy. Clinical activity and ophthalmopathy index scores were assessed. Nine age- and sex-matched healthy volunteers served as control subjects. Results: The mean 8-OHdG level was statistically significantly increased in patients having active GO compared with that of controls (17.47 vs 5.97 ng/mg of creatinine, P < .001). During and after maximal systemic corticosteroid treatment, patients had statistically significantly lower mean 8-OHdG levels (7.19 and 10.18 ng/mg of creatinine, respectively) compared with the mean level before treatment. These changes were accompanied by decreases in clinical activity and ophthalmopathy index scores. The urinary 8-OHdG levels were subsequently elevated in 2 patients having recurrent active GO when corticosteroid therapy was tapered or withdrawn. Conclusions: Oxidative stress may have a role in the pathogenesis of GO. Urinary 8-OHdG level can be used not only as a noninvasive biomarker of oxidative stress in patients having GO but also as an objective and quantitative parameter in the follow-up of patients during immunosuppressive treatment.

UR - http://www.scopus.com/inward/record.url?scp=37149024272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37149024272&partnerID=8YFLogxK

U2 - 10.1001/archopht.125.12.1652

DO - 10.1001/archopht.125.12.1652

M3 - Article

VL - 125

SP - 1652

EP - 1656

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 12

ER -